RENBP and breast cancer: The synthesized DTX-Ag-NCPs offered enhanced oral drug delivery potential of DTX (sustained blood level for 24 h, 6 folds higher half-life and 9 folds higher bioavailability) as compared to DTX suspension and cytotoxic synergism against MDA-MB-231 breast cancer cell line.